1
|
Guo P, Xue HY, Buttaro BA, Tran NT, Wong HL. Enhanced eradication of intracellular and biofilm-residing methicillin-resistant Staphylococcus aureus (MRSA) reservoirs with hybrid nanoparticles delivering rifampicin. Int J Pharm 2020; 589:119784. [PMID: 32877731 DOI: 10.1016/j.ijpharm.2020.119784] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2020] [Revised: 08/08/2020] [Accepted: 08/16/2020] [Indexed: 01/08/2023]
Abstract
Osteomyelitis carries a high risk of recurrence even after extended, aggressive antibiotic therapy. One of the key challenges is to eradicate the reservoirs of methicillin-resistant Staphylococcus aureus (MRSA) inside the host bone cells and their biofilms. Our goal is to develop rifampicin loaded lipid-polymer hybrid nanocarriers (Rf-LPN) and evaluate if they can achieve enhanced rifampicin delivery to eradicate these intracellular and biofilm-residing MRSA. After optimization of the composition, Rf-LPN demonstrated size around 110 nm in diameter that remained stable in serum-supplemented medium, drug payload up to 11.7% and sustained rifampicin release for 2 weeks. When comparing Rf-LPN with free rifampicin, moderate but significant (p < 0.05) improvement of the activities against three osteomyelitis-causing bacteria (USA300-0114, CDC-587, RP-62A) in planktonic form were observed. In comparison, the enhancements in the activities against the biofilms and intracellular MRSA by Rf-LPN were even more substantial. The MBEC50 values against USA300-0114, CDC-587, and RP-62A were 42 vs 155, 70 vs 388, and 265 ng/ml vs over 400 ng/ml, respectively, and up to 18.5-fold reduction in the intracellular MRSA counts in osteoblasts was obtained. Confocal microscope images confirmed extensive accumulation of Rf-LPN inside the biofilm matrix and MRSA-infected osteoblasts. Overall, in this proof-of-concept study we have developed and validated the strategy to exploit the nanoparticle-cell and nanoparticle-biofilm interactions with a new rifampicin nanoformulation for prevention of osteomyelitis recurrence and chronicity caused by the elusive MRSA.
Collapse
Affiliation(s)
- Pengbo Guo
- School of Pharmacy, Temple University, 3307 North Broad Street, Philadelphia, PA 19140, USA
| | - Hui Yi Xue
- School of Pharmacy, Temple University, 3307 North Broad Street, Philadelphia, PA 19140, USA
| | - Bettina A Buttaro
- Department of Microbiology, Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA
| | - Ngoc T Tran
- School of Pharmacy, Temple University, 3307 North Broad Street, Philadelphia, PA 19140, USA
| | - Ho Lun Wong
- School of Pharmacy, Temple University, 3307 North Broad Street, Philadelphia, PA 19140, USA.
| |
Collapse
|
2
|
Antitubercular nanocarrier monotherapy: Study of In Vivo efficacy and pharmacokinetics for rifampicin. J Control Release 2020; 321:312-323. [PMID: 32067995 DOI: 10.1016/j.jconrel.2020.02.026] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2019] [Revised: 01/07/2020] [Accepted: 02/13/2020] [Indexed: 02/08/2023]
Abstract
Tuberculosis represents a major global health problem for which improved approaches are needed to shorten the course of treatment and to combat the emergence of resistant strains. The development of effective and safe nanobead-based interventions can be particularly relevant for increasing the concentrations of antitubercular agents within the infected site and reducing the concentrations in the general circulation, thereby avoiding off-target toxic effects. In this work, rifampicin, a first-line antitubercular agent, was encapsulated into biocompatible and biodegradable polyester-based nanoparticles. In a well-established BALB/c mouse model of pulmonary tuberculosis, the nanoparticles provided improved pharmacokinetics and pharmacodynamics. The nanoparticles were well tolerated and much more efficient than an equivalent amount of free rifampicin.
Collapse
|
3
|
Trousil J, Syrová Z, Dal NJK, Rak D, Konefał R, Pavlova E, Matějková J, Cmarko D, Kubíčková P, Pavliš O, Urbánek T, Sedlák M, Fenaroli F, Raška I, Štěpánek P, Hrubý M. Rifampicin Nanoformulation Enhances Treatment of Tuberculosis in Zebrafish. Biomacromolecules 2019; 20:1798-1815. [PMID: 30785284 DOI: 10.1021/acs.biomac.9b00214] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Mycobacterium tuberculosis, the etiologic agent of tuberculosis, is an intracellular pathogen of alveolar macrophages. These cells avidly take up nanoparticles, even without the use of specific targeting ligands, making the use of nanotherapeutics ideal for the treatment of such infections. Methoxy poly(ethylene oxide)- block-poly(ε-caprolactone) nanoparticles of several different polymer blocks' molecular weights and sizes (20-110 nm) were developed and critically compared as carriers for rifampicin, a cornerstone in tuberculosis therapy. The polymeric nanoparticles' uptake, consequent organelle targeting and intracellular degradation were shown to be highly dependent on the nanoparticles' physicochemical properties (the cell uptake half-lives 2.4-21 min, the degradation half-lives 51.6 min-ca. 20 h after the internalization). We show that the nanoparticles are efficiently taken up by macrophages and are able to effectively neutralize the persisting bacilli. Finally, we demonstrate, using a zebrafish model of tuberculosis, that the nanoparticles are well tolerated, have a curative effect, and are significantly more efficient compared to a free form of rifampicin. Hence, these findings demonstrate that this system shows great promise, both in vitro and in vivo, for the treatment of tuberculosis.
Collapse
Affiliation(s)
- Jiří Trousil
- Institute of Macromolecular Chemistry, Czech Academy of Sciences , Heyrovského náměstí 2 , 162 00 Prague 6 , Czech Republic.,Department of Analytical Chemistry, Faculty of Science , Charles University , Hlavova 8 , 128 43 Prague 2 , Czech Republic
| | - Zdeňka Syrová
- Institute of Biology and Medical Genetics, First Faculty of Medicine , Charles University and General University Hospital in Prague , Albertov 4 , 128 00 Prague 2 , Czech Republic
| | - Nils-Jørgen K Dal
- Department of Biosciences , University of Oslo , Blindernveien 31 , 0371 Oslo , Norway
| | - Dmytro Rak
- Institute of Experimental Physics , Slovak Academy of Sciences , Watsonova 47 , 040 01 Košice , Slovakia
| | - Rafał Konefał
- Institute of Macromolecular Chemistry, Czech Academy of Sciences , Heyrovského náměstí 2 , 162 00 Prague 6 , Czech Republic
| | - Ewa Pavlova
- Institute of Macromolecular Chemistry, Czech Academy of Sciences , Heyrovského náměstí 2 , 162 00 Prague 6 , Czech Republic
| | - Jana Matějková
- Department of Medical Microbiology, Second Faculty of Medicine , Charles University and Motol University Hospital , V Úvalu 84 , 150 06 Prague 5 , Czech Republic
| | - Dušan Cmarko
- Institute of Biology and Medical Genetics, First Faculty of Medicine , Charles University and General University Hospital in Prague , Albertov 4 , 128 00 Prague 2 , Czech Republic
| | - Pavla Kubíčková
- Center of Biological Defense , Military Health Institute, Military Medical Agency , 561 66 Těchonín , Czech Republic
| | - Oto Pavliš
- Center of Biological Defense , Military Health Institute, Military Medical Agency , 561 66 Těchonín , Czech Republic
| | - Tomáš Urbánek
- Institute of Macromolecular Chemistry, Czech Academy of Sciences , Heyrovského náměstí 2 , 162 00 Prague 6 , Czech Republic
| | - Marián Sedlák
- Institute of Experimental Physics , Slovak Academy of Sciences , Watsonova 47 , 040 01 Košice , Slovakia
| | - Federico Fenaroli
- Department of Biosciences , University of Oslo , Blindernveien 31 , 0371 Oslo , Norway
| | - Ivan Raška
- Institute of Biology and Medical Genetics, First Faculty of Medicine , Charles University and General University Hospital in Prague , Albertov 4 , 128 00 Prague 2 , Czech Republic
| | - Petr Štěpánek
- Institute of Macromolecular Chemistry, Czech Academy of Sciences , Heyrovského náměstí 2 , 162 00 Prague 6 , Czech Republic
| | - Martin Hrubý
- Institute of Macromolecular Chemistry, Czech Academy of Sciences , Heyrovského náměstí 2 , 162 00 Prague 6 , Czech Republic
| |
Collapse
|